Analysts expect Kura Oncology Inc (NASDAQ:KURA) to report earnings of ($0.42) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Kura Oncology’s earnings, with estimates ranging from ($0.46) to ($0.40). Kura Oncology reported earnings of ($0.37) per share in the same quarter last year, which indicates a negative year over year growth rate of 13.5%. The firm is scheduled to report its next earnings report on Monday, March 11th.
According to Zacks, analysts expect that Kura Oncology will report full year earnings of ($1.73) per share for the current year, with EPS estimates ranging from ($1.76) to ($1.70). For the next financial year, analysts anticipate that the company will post earnings of ($1.82) per share, with EPS estimates ranging from ($1.94) to ($1.60). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Kura Oncology.
Several equities analysts have recently issued reports on the company. Piper Jaffray Companies set a $25.00 price target on Kura Oncology and gave the company a “buy” rating in a research report on Monday, December 3rd. HC Wainwright reiterated a “buy” rating and set a $31.00 price target on shares of Kura Oncology in a research report on Monday, December 3rd. Zacks Investment Research cut Kura Oncology from a “buy” rating to a “hold” rating in a research report on Friday, November 9th. ValuEngine cut Kura Oncology from a “strong-buy” rating to a “buy” rating in a research report on Friday, October 19th. Finally, BidaskClub cut Kura Oncology from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $28.17.
In related news, major shareholder Ecor1 Capital Fund Qualified, acquired 119,906 shares of Kura Oncology stock in a transaction dated Thursday, December 6th. The stock was acquired at an average cost of $13.50 per share, with a total value of $1,618,731.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 15.30% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Great Point Partners LLC boosted its stake in shares of Kura Oncology by 30.7% during the 4th quarter. Great Point Partners LLC now owns 2,769,527 shares of the company’s stock worth $38,884,000 after acquiring an additional 650,421 shares in the last quarter. BlackRock Inc. boosted its position in shares of Kura Oncology by 0.6% in the fourth quarter. BlackRock Inc. now owns 2,409,979 shares of the company’s stock worth $33,836,000 after buying an additional 13,842 shares during the period. Eagle Asset Management Inc. boosted its position in shares of Kura Oncology by 51.4% in the third quarter. Eagle Asset Management Inc. now owns 2,070,417 shares of the company’s stock worth $36,232,000 after buying an additional 703,282 shares during the period. Victory Capital Management Inc. boosted its position in shares of Kura Oncology by 10.1% in the fourth quarter. Victory Capital Management Inc. now owns 1,692,220 shares of the company’s stock worth $23,759,000 after buying an additional 155,910 shares during the period. Finally, Carillon Tower Advisers Inc. boosted its position in shares of Kura Oncology by 62.2% in the third quarter. Carillon Tower Advisers Inc. now owns 1,502,217 shares of the company’s stock worth $26,288,000 after buying an additional 576,221 shares during the period. 80.31% of the stock is owned by institutional investors and hedge funds.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Featured Article: What is the strike price in options trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.